- Home
- CUB vs MGNX Comparison
CUB vs MGNX Comparison
Compare CUB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- MGNX
- Stock Information
- Founded
- CUB 2024
- MGNX 2000
- Country
- CUB United States
- MGNX United States
- Employees
- CUB N/A
- MGNX N/A
- Industry
- CUB
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- MGNX Health Care
- Exchange
- CUB NYSE
- MGNX Nasdaq
- Market Cap
- CUB 307.3M
- MGNX 257.3M
- IPO Year
- CUB 2024
- MGNX 2013
- Fundamental
- Price
- CUB $10.04
- MGNX $3.24
- Analyst Decision
- CUB
- MGNX Buy
- Analyst Count
- CUB 0
- MGNX 11
- Target Price
- CUB N/A
- MGNX $8.57
- AVG Volume (30 Days)
- CUB 15.9K
- MGNX 770.4K
- Earning Date
- CUB 01-01-0001
- MGNX 11-05-2024
- Dividend Yield
- CUB N/A
- MGNX N/A
- EPS Growth
- CUB N/A
- MGNX N/A
- EPS
- CUB N/A
- MGNX N/A
- Revenue
- CUB N/A
- MGNX $141,329,000.00
- Revenue This Year
- CUB N/A
- MGNX $119.63
- Revenue Next Year
- CUB N/A
- MGNX N/A
- P/E Ratio
- CUB N/A
- MGNX N/A
- Revenue Growth
- CUB N/A
- MGNX 16.68
- 52 Week Low
- CUB $9.96
- MGNX $2.95
- 52 Week High
- CUB $10.49
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- MGNX 37.79
- Support Level
- CUB N/A
- MGNX $3.61
- Resistance Level
- CUB N/A
- MGNX $5.10
- Average True Range (ATR)
- CUB 0.00
- MGNX 0.35
- MACD
- CUB 0.00
- MGNX -0.10
- Stochastic Oscillator
- CUB 0.00
- MGNX 4.62
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).